Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Olon Expands On Multiple Fronts

Adds To HPAPI Capabilities In India And Sets Out Investment Plans In Italy

Executive Summary

Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.

You may also be interested in...

Olon Opens New R&D Site In Milan

Italy’s Olon has opened its new R&D hub in Milan, shortly after announcing plans to expand a key manufacturing facility in India.

Olon Expands Pipeline With Pralsetinib And Trilaciclib

API specialist Olon has announced the expansion of its pipeline with the addition of two products: pralsetinib and trilaciclib.

Italy’s Olon expands through Indian plant

Italian active pharmaceutical ingredient (API) supplier and contract development and manufacturing organisation (CDMO) Olon has expanded its global footprint by striking a deal to buy an API facility in Mahad, India, from Novartis. Describing the plant as “established and reputable”, Olon noted that it “provides a number of lifesaving medicines to the Indian healthcare system and patients around the world”.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts